New Review Links GLP-1 Drugs to Long-Term Heart Benefits
A new review of international clinical trial data suggests that GLP-1 receptor agonists, a class of medications widely used for weight loss and blood sugar control, may also reduce the risk of serious cardiovascular problems over the long term.
Researchers at Anglia Ruskin University analyzed data from more than 90,000 participants across 11 major cardiovascular outcome trials. The studies followed patients for at least one year, with average monitoring lasting nearly three years. The findings were published in Cardiovascular Diabetology — Endocrinology Reports.
The review found that people taking GLP-1 receptor agonists had about a 13% lower risk of major adverse cardiovascular events compared with those receiving a placebo. These events included heart attacks, strokes, and deaths related to cardiovascular disease. The researchers also reported lower rates of non-fatal heart attacks, non-fatal strokes, hospitalizations for heart failure, and death from any cause among those using the medications.
The benefits were seen in patients both with and without diabetes, though the strongest effects appeared among people already at high cardiovascular risk. This group included individuals with obesity, type 2 diabetes, or existing heart disease.
GLP-1 receptor agonists include medications such as semaglutide, liraglutide, and dulaglutide. These drugs have become increasingly prominent because of their role in treating obesity and managing diabetes.
The review did not identify a meaningful increase in serious safety risks, including severe hypoglycemia or acute pancreatitis, compared with placebo. However, gastrointestinal side effects such as nausea and vomiting were more common, consistent with previous findings on this drug class.
Lead author Dr. Simon Cork said the results indicate that these medicines may have implications beyond weight and glucose management. He said the findings could influence clinical practice and health policy, particularly for people with type 2 diabetes or established heart disease.
The authors suggested that broader or earlier use of GLP-1 medications could help reduce cardiovascular events in high-risk populations.